Jay Bergeron, Pfizer - Qepler Summits And Conferences

Jay Bergeron

Director, Translational Research Business Technologies
Cambridge, USA
Pfizer: One of the world's premier biopharmaceutical companies

Jay Bergeron is Director, Translational Research Business Technologies, at Pfizer responsible for technology services supporting Early Clinical Development, Precision Medicine, Target Sciences and Computational Biology.

He has been highly involved in open source and collaborative communities, including serving as the Scientific Coordinator for the IMI eTRIKS consortium which developed open source translational research software and services for academic research and public private partnerships.

Related Sessions:

Pharmaceutical R&D
Informatics Summit 2019

Improving R&D process with computational transformation: AI & ML, Advanced Data Sciences & New Methods.
  • 26 Sep 2019
  • Vienna, AT
  • Pharma
Day 1: Thursday, 26 September 2019
CASE STUDY: Multiparty medical data exchange using a digital rights block chain: Patient matching to clinical trials as an example.
  • The Healthcare IT community struggles to find «killer» blockchain apps
  • Complicated multi-party interactions are required for patient-focused data exchanges and challenge the classic cryptocurrency block chain model.
  • We implemented a multi-party clinical trial matching simulation using only a digital rights block chain (the Bitmark Blockchain).
  • The Bitmark simulation employs digital titles that are conserved and appended across ledger transactions to reference patient data and enable participants to act upon these data at designated times.
  • The specialized digital rights block may be applicable to many multiparty use cases pertinent to Medical data exchange.
View Details